☰

cached image

Stephen Walter Fesik - Publications

Affiliations: 
2009 Abbott Laboratories, Irving, TX, United States 
 2009- Biochemistry Vanderbilt University, Nashville, TN 
Website:
https://medschool.vanderbilt.edu/fesik-lab/person/stephen-w-fesik-phd
Tree Info Similar researchers PubMed Report error

232 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Teuscher KB, Mills JJ, Tian J, Han C, Meyers KM, Sai J, South TM, Crow MM, Van Meveren M, Sensintaffar JL, Zhao B, Amporndanai K, Moore WJ, Stott GM, Tansey WP, ... ... Fesik SW, et al. Structure-Based Discovery of Potent, Orally Bioavailable Benzoxazepinone-Based WD Repeat Domain 5 Inhibitors. Journal of Medicinal Chemistry. PMID 38085679 DOI: 10.1021/acs.jmedchem.3c01529  0.316
2022 Teuscher KB, Meyers KM, Wei Q, Mills JJ, Tian J, Alvarado J, Sai J, Van Meveren M, South TM, Rietz TA, Zhao B, Moore WJ, Stott GM, Tansey WP, Lee T, ... Fesik SW, et al. Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-Based Optimization. Journal of Medicinal Chemistry. PMID 35436124 DOI: 10.1021/acs.jmedchem.2c00195  0.312
2020 Sarkar D, Olejniczak ET, Phan J, Coker JA, Sai J, Arnold AL, Beesetty Y, Waterson AG, Fesik SW. Discovery of Sulfonamide-Derived Agonists of SOS1-Mediated Nucleotide Exchange on RAS Using Fragment-Based Methods. Journal of Medicinal Chemistry. PMID 32673492 DOI: 10.1021/Acs.Jmedchem.0C00511  0.39
2020 Chacon Simon S, Wang F, Thomas LR, Phan J, Zhao B, Olejniczak ET, Macdonald JD, Shaw JG, Schlund C, Payne WG, Creighton J, Stauffer S, Waterson AG, Tansey WP, Fesik SW. Discovery of WD Repeat-Containing Protein 5 (WDR5)-MYC inhibitors using fragment-based methods and structure-based design. Journal of Medicinal Chemistry. PMID 32223236 DOI: 10.1021/Acs.Jmedchem.0C00224  0.774
2020 Thomas LR, Adams CM, Fesik SW, Eischen CM, Tansey WP. Targeting MYC through WDR5. Molecular & Cellular Oncology. 7: 1709388. PMID 32158922 DOI: 10.1080/23723556.2019.1709388  0.349
2020 Kessler D, Gollner A, Gmachl M, Mantoulidis A, Martin LJ, Zoephel A, Mayer M, Covini D, Fischer S, Gerstberger T, Gmaschitz T, Goodwin C, Greb P, Häring D, Hela W, ... ... Fesik SW, et al. Reply to Tran et al.: Dimeric KRAS protein-protein interaction stabilizers. Proceedings of the National Academy of Sciences of the United States of America. PMID 32047042 DOI: 10.1073/Pnas.1921236117  0.312
2020 Zhao B, Payne WG, Sai J, Lu Z, Olejniczak ET, Fesik SW. Structural Elucidation of Peptide Binding to KLHL-12, a Substrate Specific Adapter Protein in a Cul3-Ring E3 Ligase Complex. Biochemistry. PMID 32032490 DOI: 10.1021/Acs.Biochem.9B01073  0.38
2020 Bryan AF, Wang J, Howard GC, Guarnaccia AD, Woodley CM, Aho ER, Rellinger EJ, Matlock BK, Flaherty DK, Lorey SL, Chung DH, Fesik SW, Liu Q, Weissmiller AM, Tansey WP. WDR5 is a conserved regulator of protein synthesis gene expression. Nucleic Acids Research. PMID 31996893 DOI: 10.1093/Nar/Gkaa051  0.386
2019 Tian J, Teuscher K, Aho ER, Alvarado JR, Mills JJ, Meyers KM, Gogliotti RD, Han C, Macdonald JD, Sai J, Shaw JG, Sensintaffar JL, Zhao B, Rietz TA, Thomas LR, ... ... Fesik SW, et al. Discovery and Structure-Based Optimization of Potent and Selective WD repeat domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core. Journal of Medicinal Chemistry. PMID 31858797 DOI: 10.1021/Acs.Jmedchem.9B01608  0.45
2019 Thomas LR, Adams CM, Wang J, Weissmiller AM, Creighton J, Lorey SL, Liu Q, Fesik SW, Eischen CM, Tansey WP. Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance. Proceedings of the National Academy of Sciences of the United States of America. PMID 31767764 DOI: 10.1073/Pnas.1910391116  0.369
2019 Macdonald JD, Chacon Simon S, Han C, Wang F, Shaw JG, Howes JE, Sai J, Yuh J, Camper DV, Alicie BM, Alvarado J, Nikhar S, Payne WG, Aho ER, Bauer J, ... ... Fesik SW, et al. Discovery and Optimization of Salicylic Acid-Derived Sulfonamide Inhibitors of the WD Repeat-Containing Protein 5 (WDR5)-MYC Protein-Protein Interaction. Journal of Medicinal Chemistry. PMID 31724864 DOI: 10.1021/Acs.Jmedchem.9B01411  0.767
2019 Kessler D, Gmachl M, Mantoulidis A, Martin LJ, Zoephel A, Mayer M, Gollner A, Covini D, Fischer S, Gerstberger T, Gmaschitz T, Goodwin C, Greb P, Häring D, Hela W, ... ... Fesik SW, et al. Drugging an undruggable pocket on KRAS. Proceedings of the National Academy of Sciences of the United States of America. PMID 31332011 DOI: 10.1073/Pnas.1904529116  0.37
2019 Lee T, Christov PP, Shaw S, Tarr JC, Zhao B, Veerasamy N, Jeon KO, Mills JJ, Bian Z, Sensintaffar JL, Arnold AL, Fogarty SA, Perry E, Ramsey HE, Cook R, ... ... Fesik SW, et al. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors that Demonstrate in vivo Activity in Mouse Xenograft Models of Human Cancer. Journal of Medicinal Chemistry. PMID 30929420 DOI: 10.2210/Pdb6Ne5/Pdb  0.765
2019 Aho ER, Wang J, Gogliotti RD, Howard GC, Phan J, Acharya P, Macdonald JD, Cheng K, Lorey SL, Lu B, Wenzel S, Foshage AM, Alvarado J, Wang F, Shaw JG, ... ... Fesik SW, et al. Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity. Cell Reports. 26: 2916-2928.e13. PMID 30865883 DOI: 10.1016/J.Celrep.2019.02.047  0.36
2019 Akan DT, Howes JE, Sai J, Arnold AL, Beesetty Y, Phan J, Olejniczak ET, Waterson AG, Fesik SW. Small molecule SOS1 agonists modulate MAPK and PI3K signaling via independent cellular responses. Acs Chemical Biology. PMID 30735352 DOI: 10.1021/Acschembio.8B00869  0.318
2018 Hodges TR, Abbott JR, Little AJ, Sarkar D, Salovich JM, Howes J, Akan DT, Sai J, Arnold AL, Browning C, Burns MC, Sobolik T, Sun Q, Beesetty Y, Coker J, ... ... Fesik SW, et al. Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS. Journal of Medicinal Chemistry. PMID 30205005 DOI: 10.1021/Acs.Jmedchem.8B01108  0.308
2018 Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, Boyd KL, Strickland SA, Sensintaffar J, Hogdal LJ, Ayers GD, Olejniczak ET, Fesik SW, Savona MR. A Novel MCL-1 Inhibitor Combined with Venetoclax Rescues Venetoclax Resistant Acute Myelogenous Leukemia. Cancer Discovery. PMID 30185627 DOI: 10.1158/2159-8290.Cd-18-0140  0.349
2018 Zhao B, Arnold AL, Coronel MA, Lee JH, Lee T, Olejniczak ET, Fesik SW. Understanding the Species Selectivity of Myeloid cell leukemia-1 (Mcl-1) Inhibitors. Biochemistry. PMID 30011190 DOI: 10.2210/Pdb6Dm8/Pdb  0.396
2018 Wang F, Jeon KO, Salovich JM, Macdonald JD, Alvarado J, Gogliotti RD, Phan J, Olejniczak ET, Sun Q, Wang S, Camper DV, Yuh JP, Shaw JG, Sai J, Rossanese OW, ... ... Fesik SW, et al. Discovery of Potent 2-Aryl-6,7-Dihydro-5 H-Pyrrolo[1,2- a]imidazoles as WDR5 WIN-site Inhibitors Using Fragment-Based Methods and Structure-Based Design. Journal of Medicinal Chemistry. PMID 29889518 DOI: 10.1021/Acs.Jmedchem.8B00375  0.448
2018 Abbott JR, Hodges TR, Daniels RN, Patel PA, Kennedy JP, Howes JE, Akan DT, Burns MC, Sai J, Sobolik T, Beesetty Y, Lee T, Rossanese OW, Phan J, Waterson AG, ... Fesik SW, et al. Discovery of Aminopiperidine Indoles That Activate the Guanine Nucleotide Exchange Factor SOS1 and Modulate RAS Signaling. Journal of Medicinal Chemistry. PMID 29856609 DOI: 10.2210/Pdb6Bvl/Pdb  0.334
2018 Burns MC, Howes JE, Sun Q, Little AJ, Camper DV, Abbott JR, Phan J, Lee T, Waterson AG, Rossanese OW, Fesik SW. High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling. Analytical Biochemistry. PMID 29444450 DOI: 10.1016/J.Ab.2018.01.025  0.355
2018 Howes JE, Akan DT, Burns MC, Rossanese OW, Waterson AG, Fesik SW. Small molecule-mediated activation of RAS elicits biphasic modulation of phospho ERK levels that are regulated through negative feedback on SOS1. Molecular Cancer Therapeutics. PMID 29440291 DOI: 10.1158/1535-7163.Mct-17-0666  0.301
2018 Shaw S, Bian Z, Zhao B, Tarr JC, Veerasamy N, Jeon K, Belmar J, Arnold AL, Fogarty SA, Perry E, Sensintaffar JL, Camper DV, Rossanese OW, Lee T, Olejniczak ET, ... Fesik SW, et al. Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors Using Structure-Based Design. Journal of Medicinal Chemistry. PMID 29323899 DOI: 10.1021/Acs.Jmedchem.7B01155  0.774
2018 Srivastava AK, Govindharajulu JP, Hollingshead MG, Moore WJ, Tomaino F, Banfield K, Lee T, Olejniczak ET, Sensintaffar J, Millin MD, Parchment RE, Doroshow JH, Fesik S. BAX-BAK heterodimer as a pharmacodynamic biomarker of on-target drug action of Mcl-1 inhibitors to evaluate in-vivo effectiveness. Journal of Clinical Oncology. 36: 2582-2582. DOI: 10.1200/Jco.2018.36.15_Suppl.2582  0.37
2018 Howes JE, Akan DT, Burns MC, Sun Q, Little AJ, Camper DV, Abbott JR, Phan J, Lee T, Rossanese OW, Waterson AG, Fesik SW. Abstract 865: Small molecule-mediated modulation of Ras elicits inhibition of phospho ERK signaling through negative feedback on SOS1 Cancer Research. 78: 865-865. DOI: 10.1158/1538-7445.Am2018-865  0.324
2017 Patrone JD, Waterson AG, Fesik SW. Recent advancements in the discovery of protein-protein interaction inhibitors of replication protein A. Medchemcomm. 8: 259-267. PMID 30108742 DOI: 10.1039/C6Md00460A  0.39
2017 Zhao B, Sensintaffar J, Bian Z, Belmar J, Lee T, Olejniczak ET, Fesik SW. Structure of a Myeloid cell leukemia-1 (Mcl-1) inhibitor bound to drug site 3 of Human Serum Albumin. Bioorganic & Medicinal Chemistry. PMID 28428041 DOI: 10.1016/J.Bmc.2017.03.060  0.423
2017 Howes JE, Akan DT, Alicie BM, Waterson AG, Rossanese OW, Fesik SW. Abstract PR04: Small molecule-mediated activation of Ras elicits inhibition of MAPK and PI3K signaling though pathway feedback Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-Pr04  0.304
2017 Fesik SW. Abstract IA02: Mcl-1 inhibitors for the treatment of cancer Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-Ia02  0.398
2017 Lee K, Giltnane J, Balko J, Schwarz L, Guerrero A, Hutchinson K, Hicks M, Sanchez V, Sanders M, Lee T, Olejniczak E, Fesik S, Arteaga C. Abstract 3890: Mitochondrial MCL1 maintains triple negative breast cancer stem cells and contributes to chemotherapy resistance Cancer Research. 77: 3890-3890. DOI: 10.1158/1538-7445.Am2017-3890  0.325
2016 Lee T, Bian Z, Zhao B, Hogdal LJ, Sensintaffar JL, Goodwin CM, Belmar J, Shaw S, Tarr JC, Veerasamy N, Matulis SM, Koss B, Fischer MA, Arnold AL, Camper DV, ... ... Fesik SW, et al. Discovery and Biological Characterization of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors. Febs Letters. PMID 27878989 DOI: 10.1002/1873-3468.12497  0.756
2016 Pelz NF, Bian Z, Zhao B, Shaw S, Tarr JC, Belmar J, Gregg C, Camper DV, Goodwin CM, Arnold AL, Sensintaffar JL, Friberg A, Rossanese OW, Lee T, Olejniczak ET, ... Fesik SW, et al. Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods. Journal of Medicinal Chemistry. PMID 26878343 DOI: 10.1021/Acs.Jmedchem.5B01660  0.789
2016 Patrone JD, Pelz NF, Bates BS, Souza-Fagundes EM, Vangamudi B, Camper DV, Kuznetsov AG, Browning CF, Feldkamp MD, Frank AO, Gilston BA, Olejniczak ET, Rossanese OW, Waterson AG, Chazin WJ, ... Fesik SW, et al. Identification and Optimization of Anthranilic Acid Based Inhibitors of Replication Protein A. Chemmedchem. PMID 26748787 DOI: 10.1002/Cmdc.201500479  0.444
2016 Fesik SW. Abstract SY16-02: The discovery of Mcl-1 inhibitors using fragment-based methods and structure-based design Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Sy16-02  0.43
2016 Shaw S, Tarr JC, Pelz N, Bian Z, Belmar J, Zhao B, Goodwin C, Arnold A, Sensintaffar J, Rossanese O, Lee T, Olejniczak E, Fesik S. Abstract 4331: Discovery of potent 2-Indole-acylsulfonamide Mcl-1 inhibitors using structure guided fragment-based methods Cancer Research. 76: 4331-4331. DOI: 10.1158/1538-7445.Am2016-4331  0.464
2016 Sensintaffar JL, Arnold A, Goodwin C, Hogdal L, Shaw S, Tarr JC, Lee T, Olejniczak E, Fesik SW. Abstract 3727: Small molecule Mcl-1 inhibitors induce apoptosis and death in multiple cancer subtypesin vitro Cancer Research. 76: 3727-3727. DOI: 10.1158/1538-7445.Am2016-3727  0.402
2016 Hogdal L, Sensintaffar J, Arnold A, Goodwin C, Bian Z, Shaw S, Tarr C, Lee T, Olejniczak E, Fesik S. Abstract 3726: Predicting cellular response to small molecule Mcl-1 antagonists Cancer Research. 76: 3726-3726. DOI: 10.1158/1538-7445.Am2016-3726  0.42
2016 Lee T, Bian Z, Belmar J, Shaw S, Tarr JC, Zhao B, Pelz N, Camper D, Goodwin CM, Arnold AL, Sensintaffar JL, Browning CF, Rossanese OW, Olejniczak ET, Fesik SW. Abstract 3551: Discovery of orally bioavailable novel Mcl-1 inhibitors that exhibit selective anti-proliferative activity in Mcl-1 sensitive cancer cell lines Cancer Research. 76: 3551-3551. DOI: 10.1158/1538-7445.Am2016-3551  0.407
2015 Goodwin CM, Rossanese OW, Olejniczak ET, Fesik SW. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer. Cell Death and Differentiation. 22: 2098-106. PMID 26045046 DOI: 10.1038/Cdd.2015.73  0.353
2015 Burke JP, Bian Z, Shaw S, Zhao B, Goodwin CM, Belmar J, Browning CF, Vigil D, Friberg A, Camper DV, Rossanese OW, Lee T, Olejniczak ET, Fesik SW. Discovery of tricyclic indoles that potently inhibit Mcl-1 using fragment-based methods and structure-based design. Journal of Medicinal Chemistry. 58: 3794-805. PMID 25844895 DOI: 10.1021/Jm501984F  0.789
2015 Thomas LR, Wang Q, Grieb BC, Phan J, Foshage AM, Sun Q, Olejniczak ET, Clark T, Dey S, Lorey S, Alicie B, Howard GC, Cawthon B, Ess KC, Eischen CM, ... ... Fesik SW, et al. Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC. Molecular Cell. 58: 440-52. PMID 25818646 DOI: 10.2210/Pdb6Dak/Pdb  0.375
2015 Waterson AG, Kennedy JP, Patrone JD, Pelz NF, Feldkamp MD, Frank AO, Vangamudi B, Souza-Fagundes EM, Rossanese OW, Chazin WJ, Fesik SW. Diphenylpyrazoles as replication protein a inhibitors. Acs Medicinal Chemistry Letters. 6: 140-5. PMID 25699140 DOI: 10.1021/Ml5003629  0.389
2015 Belmar J, Fesik SW. Small molecule Mcl-1 inhibitors for the treatment of cancer. Pharmacology & Therapeutics. 145: 76-84. PMID 25172548 DOI: 10.1016/J.Pharmthera.2014.08.003  0.391
2015 Waterson AG, Kennedy P, Patrone JD, Pelz NF, Frank AO, Vangamudi B, Camper DV, Souza-Fagundes EM, Feldkamp MD, Olejniczak ET, Rossanese OW, Chazin WJ, Fesik SW. Abstract 3695: Discovery of probes to evaluate the disruption of the protein-protein interactions mediated by RPA70N Cancer Research. 75: 3695-3695. DOI: 10.1158/1538-7445.Am2015-3695  0.336
2014 Harner MJ, Chauder BA, Phan J, Fesik SW. Fragment-based screening of the bromodomain of ATAD2. Journal of Medicinal Chemistry. 57: 9687-92. PMID 25314628 DOI: 10.1021/Jm501035J  0.348
2014 Sun Q, Phan J, Friberg AR, Camper DV, Olejniczak ET, Fesik SW. A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand. Journal of Biomolecular Nmr. 60: 11-4. PMID 25087006 DOI: 10.1007/S10858-014-9849-8  0.358
2014 Burns MC, Sun Q, Daniels RN, Camper D, Kennedy JP, Phan J, Olejniczak ET, Lee T, Waterson AG, Rossanese OW, Fesik SW. Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange. Proceedings of the National Academy of Sciences of the United States of America. 111: 3401-6. PMID 24550516 DOI: 10.1073/Pnas.1315798111  0.316
2014 Frank AO, Vangamudi B, Feldkamp MD, Souza-Fagundes EM, Luzwick JW, Cortez D, Olejniczak ET, Waterson AG, Rossanese OW, Chazin WJ, Fesik SW. Discovery of a potent stapled helix peptide that binds to the 70N domain of replication protein A. Journal of Medicinal Chemistry. 57: 2455-61. PMID 24491171 DOI: 10.1021/Jm401730Y  0.406
2014 Fesik SW. Abstract IA17: Discovery of K-Ras inhibitors for the treatment of cancer Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-Ia17  0.308
2014 Fesik SW. Abstract IA13: Discovery of K-Ras inhibitors for the treatment of cancer Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-Ia13  0.308
2014 Rossanese OW, Burns MC, Sun Q, Daniels RN, Camper DV, Kennedy JP, Phan J, Olejniczak ET, Lee T, Waterson AG, Fesik SW. Abstract 4417: Targeting Ras with small molecules that activate SOS-mediated nucleotide exchange Cancer Research. 74: 4417-4417. DOI: 10.1158/1538-7445.Am2014-4417  0.333
2014 Waterson AG, Frank AO, Vandgamudi B, Feldkamp MD, Souza-Fagundes EM, Luzwick JW, Cortez D, Olejniczak ET, Rossanese OW, Chazin WJ, Fesik SW. Abstract 3232: Optimization of a potent stapled helix peptide that binds to Replication Protein A Cancer Research. 74: 3232-3232. DOI: 10.1158/1538-7445.Am2014-3232  0.413
2013 Frank AO, Feldkamp MD, Kennedy JP, Waterson AG, Pelz NF, Patrone JD, Vangamudi B, Camper DV, Rossanese OW, Chazin WJ, Fesik SW. Discovery of a potent inhibitor of replication protein a protein-protein interactions using a fragment-linking approach. Journal of Medicinal Chemistry. 56: 9242-50. PMID 24147804 DOI: 10.1021/Jm401333U  0.424
2013 Feldkamp MD, Frank AO, Kennedy JP, Patrone JD, Vangamudi B, Waterson AG, Fesik SW, Chazin WJ. Surface reengineering of RPA70N enables cocrystallization with an inhibitor of the replication protein A interaction motif of ATR interacting protein. Biochemistry. 52: 6515-24. PMID 23962067 DOI: 10.1021/Bi400542Z  0.417
2013 Patrone JD, Kennedy JP, Frank AO, Feldkamp MD, Vangamudi B, Pelz NF, Rossanese OW, Waterson AG, Chazin WJ, Fesik SW. Discovery of Protein-Protein Interaction Inhibitors of Replication Protein A. Acs Medicinal Chemistry Letters. 4: 601-605. PMID 23914285 DOI: 10.1021/Ml400032Y  0.426
2013 Harner MJ, Frank AO, Fesik SW. Fragment-based drug discovery using NMR spectroscopy. Journal of Biomolecular Nmr. 56: 65-75. PMID 23686385 DOI: 10.1007/S10858-013-9740-Z  0.376
2013 Friberg A, Vigil D, Zhao B, Daniels RN, Burke JP, Garcia-Barrantes PM, Camper D, Chauder BA, Lee T, Olejniczak ET, Fesik SW. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. Journal of Medicinal Chemistry. 56: 15-30. PMID 23244564 DOI: 10.1021/Jm301448P  0.483
2013 Vangamudi B, Frank AO, Souza-Fagundes EM, Feldkamp MD, Olejniczak ET, Rossanese OW, Fesik SW. Abstract 3340: Stapled helix peptides as probes to evaluate targeted disruption of protein-protein interactions mediated by RPA70N. Cancer Research. 73: 3340-3340. DOI: 10.1158/1538-7445.Am2013-3340  0.406
2013 Waterson AG, Patrone JD, Kennedy JP, Pelz NF, Frank AO, Vandgamudi B, Feldkamp MD, Souza-Fagundes EM, Rossanese OW, Chazin WJ, Fesik SW. Abstract 2473: Fragment-based discovery of inhibitors of replication protein A protein-protein interactions. Cancer Research. 73: 2473-2473. DOI: 10.1158/1538-7445.Am2013-2473  0.455
2013 Lee T, Friberg A, Vigil D, Zhao B, Daniels RN, Burke JP, Garcia-Barrantes PM, Camper D, Chauder BA, Olejniczak ET, Fesik SW. Abstract 2350: Discovery of potent and selective Mcl-1 inhibitors using fragment-based methods and structure-based design. Cancer Research. 73: 2350-2350. DOI: 10.1158/1538-7445.Am2013-2350  0.397
2013 Burns M, Sun Q, Daniels R, Kennedy JP, Camper D, Phan J, Olejniczak E, Lee T, Waterson A, Rossanese O, Fesik S. Abstract PR01: Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-Pr01  0.322
2013 Fesik SW. Abstract CN04-02: Discovery of Mcl-1 inhibitors using fragment-based methods. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-Cn04-02  0.399
2012 Sun Q, Burke JP, Phan J, Burns MC, Olejniczak ET, Waterson AG, Lee T, Rossanese OW, Fesik SW. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angewandte Chemie (International Ed. in English). 51: 6140-3. PMID 22566140 DOI: 10.1002/Anie.201201358  0.305
2012 Souza-Fagundes EM, Frank AO, Feldkamp MD, Dorset DC, Chazin WJ, Rossanese OW, Olejniczak ET, Fesik SW. A high-throughput fluorescence polarization anisotropy assay for the 70N domain of replication protein A. Analytical Biochemistry. 421: 742-9. PMID 22197419 DOI: 10.1016/J.Ab.2011.11.025  0.415
2012 Fesik SW. Abstract IA10: Targeting K-Ras for the treatment of pancreatic cancer. Cancer Research. 72. DOI: 10.1158/1538-7445.Panca2012-Ia10  0.339
2012 Vangamudi B, Ayres AE, Burke JP, Waterson AG, Rossanese OW, Fesik SW. Abstract 1813: Evaluation of TBK1 as a novel cancer target in the K-Ras pathway Cancer Research. 72: 1813-1813. DOI: 10.1158/1538-7445.Am2012-1813  0.31
2011 Lu Y, Muller M, Smith D, Dutta B, Komurov K, Iadevaia S, Ruths D, Tseng JT, Yu S, Yu Q, Nakhleh L, Balazsi G, Donnelly J, Schurdak M, Morgan-Lappe S, ... Fesik S, et al. Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene. 30: 4567-77. PMID 21666717 DOI: 10.1038/Onc.2011.164  0.311
2010 Petros AM, Huth JR, Oost T, Park CM, Ding H, Wang X, Zhang H, Nimmer P, Mendoza R, Sun C, Mack J, Walter K, Dorwin S, Gramling E, Ladror U, ... ... Fesik SW, et al. Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR. Bioorganic & Medicinal Chemistry Letters. 20: 6587-91. PMID 20870405 DOI: 10.1016/J.Bmcl.2010.09.033  0.391
2010 Shah OJ, Lin X, Li L, Huang X, Li J, Anderson MG, Tang H, Rodriguez LE, Warder SE, McLoughlin S, Chen J, Palma J, Glaser KB, Donawho CK, Fesik SW, et al. Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization. Proceedings of the National Academy of Sciences of the United States of America. 107: 12634-9. PMID 20616035 DOI: 10.1073/Pnas.0913615107  0.344
2010 Ackler S, Mitten MJ, Foster K, Oleksijew A, Refici M, Tahir SK, Xiao Y, Tse C, Frost DJ, Fesik SW, Rosenberg SH, Elmore SW, Shoemaker AR. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemotherapy and Pharmacology. 66: 869-80. PMID 20099064 DOI: 10.1007/S00280-009-1232-1  0.306
2008 Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A, Refici M, Schlessinger S, Wang B, Chemburkar SR, Bauch J, Tse C, Frost DJ, Fesik SW, Rosenberg SH, Elmore SW, et al. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Molecular Cancer Therapeutics. 7: 3265-74. PMID 18852130 DOI: 10.1158/1535-7163.Mct-08-0268  0.344
2008 Park CM, Bruncko M, Adickes J, Bauch J, Ding H, Kunzer A, Marsh KC, Nimmer P, Shoemaker AR, Song X, Tahir SK, Tse C, Wang X, Wendt MD, Yang X, ... ... Fesik SW, et al. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. Journal of Medicinal Chemistry. 51: 6902-15. PMID 18841882 DOI: 10.1021/Jm800669S  0.397
2008 Zheng M, Morgan-Lappe SE, Yang J, Bockbrader KM, Pamarthy D, Thomas D, Fesik SW, Sun Y. Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2. Cancer Research. 68: 7570-8. PMID 18794145 DOI: 10.1158/0008-5472.Can-08-0632  0.333
2008 Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M, Ferguson D, Oleksijew A, O'Connor JM, Wang B, Frost DJ, Bauch J, Marsh K, Tahir SK, Yang X, Tse C, ... Fesik SW, et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 3268-77. PMID 18519752 DOI: 10.1158/1078-0432.Ccr-07-4622  0.326
2008 Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, ... Fesik S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Research. 68: 3421-8. PMID 18451170 DOI: 10.1158/0008-5472.Can-07-5836  0.356
2008 Lin X, David CA, Donnelly JB, Michaelides M, Chandel NS, Huang X, Warrior U, Weinberg F, Tormos KV, Fesik SW, Shen Y. A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation. Proceedings of the National Academy of Sciences of the United States of America. 105: 174-9. PMID 18172210 DOI: 10.1073/Pnas.0706585104  0.359
2007 Huth JR, Park C, Petros AM, Kunzer AR, Wendt MD, Wang X, Lynch CL, Mack JC, Swift KM, Judge RA, Chen J, Richardson PL, Jin S, Tahir SK, Matayoshi ED, ... ... Fesik SW, et al. Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies. Chemical Biology & Drug Design. 70: 1-12. PMID 17630989 DOI: 10.1111/J.1747-0285.2007.00535.X  0.39
2007 Lerner CG, Hajduk PJ, Wagner R, Wagenaar FL, Woodall C, Gu YG, Searle XB, Florjancic AS, Zhang T, Clark RF, Cooper CS, Mack JC, Yu L, Cai M, Betz SF, ... ... Fesik SW, et al. From bacterial genomes to novel antibacterial agents: discovery, characterization, and antibacterial activity of compounds that bind to HI0065 (YjeE) from Haemophilus influenzae. Chemical Biology & Drug Design. 69: 395-404. PMID 17581233 DOI: 10.1111/J.1747-0285.2007.00521.X  0.426
2007 Morgan-Lappe SE, Tucker LA, Huang X, Zhang Q, Sarthy AV, Zakula D, Vernetti L, Schurdak M, Wang J, Fesik SW. Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. Cancer Research. 67: 4390-8. PMID 17483353 DOI: 10.1158/0008-5472.Can-06-4132  0.366
2007 Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, Warner RB, Ng SC, Fesik SW, Elmore SW, Rosenberg SH, Tse C. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Research. 67: 1176-83. PMID 17283153 DOI: 10.1158/0008-5472.Can-06-2203  0.33
2007 Bruncko M, Oost TK, Belli BA, Ding H, Joseph MK, Kunzer A, Martineau D, McClellan WJ, Mitten M, Ng SC, Nimmer PM, Oltersdorf T, Park CM, Petros AM, Shoemaker AR, ... ... Fesik SW, et al. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. Journal of Medicinal Chemistry. 50: 641-62. PMID 17256834 DOI: 10.1021/Jm061152T  0.418
2007 Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA, Fesik SW, Shen Y. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene. 26: 3972-9. PMID 17173063 DOI: 10.1038/Sj.Onc.1210166  0.363
2006 Shoemaker AR, Oleksijew A, Bauch J, Belli BA, Borre T, Bruncko M, Deckwirth T, Frost DJ, Jarvis K, Joseph MK, Marsh K, McClellan W, Nellans H, Ng S, Nimmer P, ... ... Fesik SW, et al. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Research. 66: 8731-9. PMID 16951189 DOI: 10.1158/0008-5472.Can-06-0367  0.361
2006 Li L, Lin X, Shoemaker AR, Albert DH, Fesik SW, Shen Y. Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4747-54. PMID 16899626 DOI: 10.1158/1078-0432.Ccr-05-2842  0.334
2006 Wendt MD, Shen W, Kunzer A, McClellan WJ, Bruncko M, Oost TK, Ding H, Joseph MK, Zhang H, Nimmer PM, Ng SC, Shoemaker AR, Petros AM, Oleksijew A, Marsh K, ... ... Fesik SW, et al. Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. Journal of Medicinal Chemistry. 49: 1165-81. PMID 16451081 DOI: 10.1021/Jm050754U  0.39
2006 Petros AM, Dinges J, Augeri DJ, Baumeister SA, Betebenner DA, Bures MG, Elmore SW, Hajduk PJ, Joseph MK, Landis SK, Nettesheim DG, Rosenberg SH, Shen W, Thomas S, Wang X, ... ... Fesik SW, et al. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. Journal of Medicinal Chemistry. 49: 656-63. PMID 16420051 DOI: 10.1021/Jm0507532  0.44
2006 Morgan-Lappe S, Woods KW, Li Q, Anderson MG, Schurdak ME, Luo Y, Giranda VL, Fesik SW, Leverson JD. RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors. Oncogene. 25: 1340-8. PMID 16247451 DOI: 10.1038/Sj.Onc.1209169  0.338
2006 Shoemaker AR, Mitten MJ, Oleksijew A, O’Connor JM, Wang B, Ackler S, Joseph M, Zhang H, Nimmer P, Xiao Y, Tse C, Frost DJ, Fesik SW, Rosenberg SH, Elmore SW. The Bcl-2 Family Inhibitor ABT-263 Shows Significant Anti-Tumor Efficacy in Models of B Cell Non-Hodgkin’s Lymphoma. Blood. 108: 825-825. DOI: 10.1182/Blood.V108.11.825.825  0.317
2005 Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nature Reviews. Cancer. 5: 876-85. PMID 16239906 DOI: 10.1038/Nrc1736  0.349
2005 Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, ... ... Fesik SW, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 435: 677-81. PMID 15902208 DOI: 10.1038/Nature03579  0.436
2005 Hajduk PJ, Huth JR, Fesik SW. Druggability indices for protein targets derived from NMR-based screening data. Journal of Medicinal Chemistry. 48: 2518-25. PMID 15801841 DOI: 10.1021/Jm049131R  0.421
2005 Park CM, Sun C, Olejniczak ET, Wilson AE, Meadows RP, Betz SF, Elmore SW, Fesik SW. Non-peptidic small molecule inhibitors of XIAP. Bioorganic & Medicinal Chemistry Letters. 15: 771-5. PMID 15664855 DOI: 10.1016/J.Bmcl.2004.11.010  0.331
2005 Fesik SW. Erratum: Promoting apoptosis as a strategy for cancer drug discovery Nature Reviews Cancer. 5: 995-995. DOI: 10.1038/Nrc1776  0.313
2004 Huth JR, Yu L, Collins I, Mack J, Mendoza R, Isaac B, Braddock DT, Muchmore SW, Comess KM, Fesik SW, Clore GM, Levens D, Hajduk PJ. NMR-driven discovery of benzoylanthranilic acid inhibitors of far upstream element binding protein binding to the human oncogene c-myc promoter. Journal of Medicinal Chemistry. 47: 4851-7. PMID 15369388 DOI: 10.1021/Jm0497803  0.424
2004 Liu Z, Olejniczak ET, Fesik SW. Over-expression of the human MDM2 p53 binding domain by fusion to a p53 transactivation peptide. Protein Expression and Purification. 37: 493-8. PMID 15358376 DOI: 10.1016/J.Pep.2004.06.036  0.345
2004 Oost TK, Sun C, Armstrong RC, Al-Assaad AS, Betz SF, Deckwerth TL, Ding H, Elmore SW, Meadows RP, Olejniczak ET, Oleksijew A, Oltersdorf T, Rosenberg SH, Shoemaker AR, Tomaselli KJ, ... ... Fesik SW, et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer Journal of Medicinal Chemistry. 47: 4417-4426. PMID 15317454 DOI: 10.1021/Jm040037K  0.449
2004 Semizarov D, Kroeger P, Fesik S. siRNA-mediated gene silencing: a global genome view Nucleic Acids Research. 32: 3836-3845. PMID 15272085 DOI: 10.1093/Nar/Gkh714  0.306
2004 Huang Q, Yu L, Petros AM, Gunasekera A, Liu Z, Xu N, Hajduk P, Mack J, Fesik SW, Olejniczak ET. Structure of the N-terminal RNA-binding domain of the SARS CoV nucleocapsid protein. Biochemistry. 43: 6059-63. PMID 15147189 DOI: 10.1021/Bi036155B  0.405
2004 Petros AM, Olejniczak ET, Fesik SW. Structural biology of the Bcl-2 family of proteins. Biochimica Et Biophysica Acta. 1644: 83-94. PMID 14996493 DOI: 10.1016/J.Bbamcr.2003.08.012  0.401
2004 Petros AM, Gunasekera A, Xu N, Olejniczak ET, Fesik SW. Defining the p53 DNA-binding domain/Bcl-x(L)-binding interface using NMR. Febs Letters. 559: 171-4. PMID 14960327 DOI: 10.1016/S0014-5793(04)00059-6  0.352
2003 Huang Q, Petros AM, Virgin HW, Fesik SW, Olejniczak ET. Solution structure of the BHRF1 protein from Epstein-Barr virus, a homolog of human Bcl-2. Journal of Molecular Biology. 332: 1123-30. PMID 14499614 DOI: 10.1016/J.Jmb.2003.08.007  0.392
2003 Hajduk PJ, Mendoza R, Petros AM, Huth JR, Bures M, Fesik SW, Martin YC. Ligand binding to domain-3 of human serum albumin: A chemometric analysis Journal of Computer-Aided Molecular Design. 17: 93-102. PMID 13677478 DOI: 10.1023/A:1025305520585  0.378
2003 Liu G, Szczepankiewicz BG, Pei Z, Janowick DA, Xin Z, Hajduk PJ, Abad-Zapatero C, Liang H, Hutchins CW, Fesik SW, Ballaron SJ, Stashko MA, Lubben T, Mika AK, Zinker BA, et al. Discovery and structure-activity relationship of oxalylarylaminobenzoic acids as inhibitors of protein tyrosine phosphatase 1B. Journal of Medicinal Chemistry. 46: 2093-103. PMID 12747781 DOI: 10.1021/Jm0205696  0.406
2003 Yu L, Oost TK, Schkeryantz JM, Yang J, Janowick D, Fesik SW. Discovery of aminoglycoside mimetics by NMR-based screening of Escherichia coli A-site RNA. Journal of the American Chemical Society. 125: 4444-50. PMID 12683814 DOI: 10.1021/Ja021354O  0.342
2003 Szczepankiewicz BG, Liu G, Hajduk PJ, Abad-Zapatero C, Pei Z, Xin Z, Lubben TH, Trevillyan JM, Stashko MA, Ballaron SJ, Liang H, Huang F, Hutchins CW, Fesik SW, Jirousek MR. Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. Journal of the American Chemical Society. 125: 4087-96. PMID 12670229 DOI: 10.1021/Ja0296733  0.403
2003 Zou H, Yang R, Hao J, Wang J, Sun C, Fesik SW, Wu JC, Tomaselli KJ, Armstrong RC. Regulation of the Apaf-1/caspase-9 apoptosome by caspase-3 and XIAP. The Journal of Biological Chemistry. 278: 8091-8. PMID 12506111 DOI: 10.1074/Jbc.M204783200  0.313
2002 Hajduk PJ, Betz SF, Mack J, Ruan X, Towne DL, Lerner CG, Beutel BA, Fesik SW. A strategy for high-throughput assay development using leads derived from nuclear magnetic resonance-based screening. Journal of Biomolecular Screening. 7: 429-32. PMID 14599358 DOI: 10.1177/108705702237674  0.389
2002 Hajduk PJ, Shuker SB, Nettesheim DG, Craig R, Augeri DJ, Betebenner D, Albert DH, Guo Y, Meadows RP, Xu L, Michaelides M, Davidsen SK, Fesik SW. NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability. Journal of Medicinal Chemistry. 45: 5628-39. PMID 12477346 DOI: 10.1021/Jm020160G  0.392
2002 Huang Q, Petros AM, Virgin HW, Fesik SW, Olejniczak ET. Solution structure of a Bcl-2 homolog from Kaposi sarcoma virus. Proceedings of the National Academy of Sciences of the United States of America. 99: 3428-33. PMID 11904405 DOI: 10.1073/Pnas.062525799  0.368
2001 Fesik SW, Shi Y. Structural biology. Controlling the caspases. Science (New York, N.Y.). 294: 1477-8. PMID 11711663 DOI: 10.1126/Science.1062236  0.335
2001 Mao H, Hajduk PJ, Craig R, Bell R, Borre T, Fesik SW. Rational design of diflunisal analogues with reduced affinity for human serum albumin. Journal of the American Chemical Society. 123: 10429-35. PMID 11673972 DOI: 10.1021/Ja015955B  0.454
2001 Yu L, Mack J, Hajduk P, Fesik SW. Structure of the N-terminal region of Haemophilus influenzae H10017: implications for function. Journal of Biomolecular Nmr. 20: 105-10. PMID 11495242 DOI: 10.1023/A:1011264300726  0.354
2001 Yu L, Gunasekera AH, Mack J, Olejniczak ET, Chovan LE, Ruan X, Towne DL, Lerner CG, Fesik SW. Solution structure and function of a conserved protein SP14.3 encoded by an essential Streptococcus pneumoniae gene. Journal of Molecular Biology. 311: 593-604. PMID 11493012 DOI: 10.1006/Jmbi.2001.4894  0.369
2001 Liu G, Huth JR, Olejniczak ET, Mendoza R, DeVries P, Leitza S, Reilly EB, Okasinski GF, Fesik SW, von Geldern TW. Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties. Journal of Medicinal Chemistry. 44: 1202-10. PMID 11312920 DOI: 10.1021/Jm000503F  0.422
2001 Riedl SJ, Renatus M, Schwarzenbacher R, Zhou Q, Sun C, Fesik SW, Liddington RC, Salvesen GS. Structural basis for the inhibition of caspase-3 by XIAP Cell. 104: 791-800. PMID 11257232 DOI: 10.1016/S0092-8674(01)00274-4  0.387
2001 Petros AM, Medek A, Nettesheim DG, Kim DH, Yoon HS, Swift K, Matayoshi ED, Oltersdorf T, Fesik SW. Solution structure of the antiapoptotic protein bcl-2. Proceedings of the National Academy of Sciences of the United States of America. 98: 3012-7. PMID 11248023 DOI: 10.1073/Pnas.041619798  0.409
2000 Petros AM, Nettesheim DG, Wang Y, Olejniczak ET, Meadows RP, Mack J, Swift K, Matayoshi ED, Zhang H, Thompson CB, Fesik SW. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Science : a Publication of the Protein Society. 9: 2528-34. PMID 11206074 DOI: 10.1110/Ps.9.12.2528  0.351
2000 Medek A, Olejniczak ET, Meadows RP, Fesik SW. An approach for high-throughput structure determination of proteins by NMR spectroscopy. Journal of Biomolecular Nmr. 18: 229-38. PMID 11142513 DOI: 10.1023/A:1026544801001  0.381
2000 Liu Z, Sun C, Olejniczak ET, Meadows RP, Betz SF, Oost T, Herrmann J, Wu JC, Fesik SW. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature. 408: 1004-8. PMID 11140637 DOI: 10.1038/35050006  0.437
2000 Hajduk PJ, Gomtsyan A, Didomenico S, Cowart M, Bayburt EK, Solomon L, Severin J, Smith R, Walter K, Holzman TF, Stewart A, McGaraughty S, Jarvis MF, Kowaluk EA, Fesik SW. Design of adenosine kinase inhibitors from the NMR-based screening of fragments. Journal of Medicinal Chemistry. 43: 4781-6. PMID 11123986 DOI: 10.1021/Jm000373A  0.375
2000 Mao H, Gunasekera AH, Fesik SW. Expression, refolding, and isotopic labeling of human serum albumin domains for NMR spectroscopy. Protein Expression and Purification. 20: 492-9. PMID 11087689 DOI: 10.1006/Prep.2000.1330  0.397
2000 Hajduk PJ, Boyd S, Nettesheim D, Nienaber V, Severin J, Smith R, Davidson D, Rockway T, Fesik SW. Identification of novel inhibitors of urokinase via NMR-based screening. Journal of Medicinal Chemistry. 43: 3862-6. PMID 11052791 DOI: 10.1021/Jm0002228  0.385
2000 Losonczi JA, Olejniczak ET, Betz SF, Harlan JE, Mack J, Fesik SW. NMR studies of the anti-apoptotic protein Bcl-xL in micelles. Biochemistry. 39: 11024-33. PMID 10998239 DOI: 10.1021/Bi000919V  0.356
2000 Hajduk PJ, Bures M, Praestgaard J, Fesik SW. Privileged molecules for protein binding identified from NMR-based screening. Journal of Medicinal Chemistry. 43: 3443-7. PMID 10978192 DOI: 10.1021/Jm000164Q  0.45
2000 Datta SR, Katsov A, Hu L, Petros A, Fesik SW, Yaffe MB, Greenberg ME. 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Molecular Cell. 6: 41-51. PMID 10949026 DOI: 10.1016/S1097-2765(05)00012-2  0.326
2000 Sun C, Cai M, Meadows RP, Xu N, Gunasekera AH, Herrmann J, Wu JC, Fesik SW. NMR structure and mutagenesis of the third Bir domain of the inhibitor of apoptosis protein XIAP. The Journal of Biological Chemistry. 275: 33777-81. PMID 10934209 DOI: 10.1074/Jbc.M006226200  0.391
2000 Huth JR, Olejniczak ET, Mendoza R, Liang H, Harris EA, Lupher ML, Wilson AE, Fesik SW, Staunton DE. NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding. Proceedings of the National Academy of Sciences of the United States of America. 97: 5231-6. PMID 10805782 DOI: 10.1073/Pnas.97.10.5231  0.367
2000 Medek A, Hajduk PJ, Mack aJ, Fesik SW. The Use of Differential Chemical Shifts for Determining the Binding Site Location and Orientation of Protein-Bound Ligands Journal of the American Chemical Society. 122: 1241-1242. DOI: 10.1021/Ja993921M  0.357
2000 Hajduk PJ, Augeri DJ, Mack J, Mendoza R, Yang J, Betz aSF, Fesik SW. NMR-Based Screening of Proteins Containing 13C-Labeled Methyl Groups Journal of the American Chemical Society. 122: 7898-7904. DOI: 10.1021/Ja000350L  0.354
1999 Hajduk PJ, Meadows RP, Fesik SW. NMR-based screening in drug discovery. Quarterly Reviews of Biophysics. 32: 211-40. PMID 11194565 DOI: 10.1017/S0033583500003528  0.396
1999 Sun C, Cai M, Gunasekera AH, Meadows RP, Wang H, Chen J, Zhang H, Wu W, Xu N, Ng SC, Fesik SW. NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP. Nature. 401: 818-22. PMID 10548111 DOI: 10.1038/44617  0.404
1999 Hajduk PJ, Dinges J, Schkeryantz JM, Janowick D, Kaminski M, Tufano M, Augeri DJ, Petros A, Nienaber V, Zhong P, Hammond R, Coen M, Beutel B, Katz L, Fesik SW. Novel inhibitors of Erm methyltransferases from NMR and parallel synthesis. Journal of Medicinal Chemistry. 42: 3852-9. PMID 10508434 DOI: 10.1021/Jm990293A  0.412
1999 Hajduk PJ, Zhou MM, Fesik SW. NMR-based discovery of phosphotyrosine mimetics that bind to the LCK SH2 domain Bioorganic and Medicinal Chemistry Letters. 9: 2403-2406. PMID 10476877 DOI: 10.1016/S0960-894X(99)00403-5  0.573
1999 Cai M, Wang H, Olejniczak ET, Meadows RP, Gunasekera AH, Xu N, Fesik SW. Accurate measurement of H(N)-H(alpha) residual dipolar couplings in proteins. Journal of Magnetic Resonance (San Diego, Calif. : 1997). 139: 451-3. PMID 10423386 DOI: 10.1006/Jmre.1999.1819  0.316
1999 Muegge I, Martin YC, Hajduk PJ, Fesik SW. Evaluation of PMF scoring in docking weak ligands to the FK506 binding protein Journal of Medicinal Chemistry. 42: 2498-2503. PMID 10411471 DOI: 10.1021/Jm990073X  0.392
1999 Hajduk PJ, Gerfin T, Boehlen JM, Häberli M, Marek D, Fesik SW. High-throughput nuclear magnetic resonance-based screening. Journal of Medicinal Chemistry. 42: 2315-7. PMID 10395471 DOI: 10.1021/Jm9901475  0.36
1999 Olejniczak ET, Meadows RP, Wang H, Cai M, Nettesheim DG, Fesik SW. Improved NMR Structures of Protein/Ligand Complexes Using Residual Dipolar Couplings Journal of the American Chemical Society. 121: 9249-9250. DOI: 10.1021/Ja992139J  0.349
1999 Wang H, Janowick DA, Schkeryantz JM, Liu X, Fesik SW. A Method For Assigning Phenylalanines In Proteins Journal of the American Chemical Society. 121: 1611-1612. DOI: 10.1021/Ja983897X  0.305
1998 Liu X, Wang H, Eberstadt M, Schnuchel A, Olejniczak ET, Meadows RP, Schkeryantz JM, Janowick DA, Harlan JE, Harris EA, Staunton DE, Fesik SW. NMR structure and mutagenesis of the N-terminal Dbl homology domain of the nucleotide exchange factor Trio. Cell. 95: 269-77. PMID 9790533 DOI: 10.1016/S0092-8674(00)81757-2  0.324
1998 Betz SF, Schnuchel A, Wang H, Olejniczak ET, Meadows RP, Lipsky BP, Harris EA, Staunton DE, Fesik SW. Solution structure of the cytohesin-1 (B2-1) Sec7 domain and its interaction with the GTPase ADP ribosylation factor 1. Proceedings of the National Academy of Sciences of the United States of America. 95: 7909-14. PMID 9653114 DOI: 10.1073/Pnas.95.14.7909  0.406
1998 Eberstadt M, Huang B, Chen Z, Meadows RP, Ng SC, Zheng L, Lenardo MJ, Fesik SW. NMR structure and mutagenesis of the FADD (Mort1) death-effector domain. Nature. 392: 941-5. PMID 9582077 DOI: 10.1038/31972  0.345
1998 Hajduk PJ, Sheppard G, Nettesheim DG, Olejniczak ET, Shuker SB, Meadows RP, Steinman DH, Carrera GM, Marcotte PA, Severin J, Walter K, Smith H, Gubbins E, Simmer R, Holzman TF, ... ... Fesik SW, et al. Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR Chemtracts. 11: 57-61. DOI: 10.1021/Ja9702778  0.406
1997 Eberstadt M, Huang B, Olejniczak ET, Fesik SW. The lymphoproliferation mutation in Fas locally unfolds the Fas death domain Nature Structural & Molecular Biology. 4: 983-985. PMID 9406545 DOI: 10.1038/Nsb1297-983  0.34
1997 Liang H, Fesik SW. Three-dimensional structures of proteins involved in programmed cell death. Journal of Molecular Biology. 274: 291-302. PMID 9405139 DOI: 10.1006/Jmbi.1997.1415  0.334
1997 Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for proteins. Science (New York, N.Y.). 278: 497,499. PMID 9381145 DOI: 10.1126/Science.278.5337.497  0.349
1997 Hajduk PJ, Dinges J, Miknis GF, Merlock M, Middleton T, Kempf DJ, Egan DA, Walter KA, Robins TS, Shuker SB, Holzman TF, Fesik SW. NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein. Journal of Medicinal Chemistry. 40: 3144-50. PMID 9379433 DOI: 10.1021/Jm9703404  0.385
1997 Kelekar A, Chang BS, Harlan JE, Fesik SW, Thompson CB. Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL Molecular and Cellular Biology. 17: 7040-7046. PMID 9372935 DOI: 10.1128/Mcb.17.12.7040  0.402
1997 Ravichandran KS, Zhou MM, Pratt JC, Harlan JE, Walk SF, Fesik SW, Burakoff SJ. Evidence for a requirement for both phospholipid and phosphotyrosine binding via the Shc phosphotyrosine-finding domain in vivo Molecular and Cellular Biology. 17: 5540-5549. PMID 9271429 DOI: 10.1128/Mcb.17.9.5540  0.347
1997 Yu L, Petros AM, Schnuchel A, Zhong P, Severin JM, Walter K, Holzman TF, Fesik SW. Solution structure of an rRNA methyltransferase (ErmAM) that confers macrolide-lincosamide-streptogramin antibiotic resistance. Nature Structural Biology. 4: 483-9. PMID 9187657 DOI: 10.1038/Nsb0697-483  0.347
1997 Chang BS, Minn AJ, Muchmore SW, Fesik SW, Thompson CB. Identification of a novel regulatory domain in Bcl‐xL and Bcl‐2 The Embo Journal. 16: 968-977. PMID 9118958 DOI: 10.1093/Emboj/16.5.968  0.369
1997 Olejniczak ET, Zhou MM, Fesik SW. Changes in the NMR-derived motional parameters of the insulin receptor substrate 1 phosphotyrosine binding domain upon binding to an interleukin 4 receptor phosphopeptide Biochemistry. 36: 4118-4124. PMID 9100005 DOI: 10.1021/Bi963050I  0.554
1997 Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M, Yoon HS, Shuker SB, Chang BS, Minn AJ, Thompson CB, Fesik SW. Structure of Bcl-x(L)-Bak peptide complex: Recognition between regulators of apoptosis Science. 275: 983-986. PMID 9020082 DOI: 10.1126/Science.275.5302.983  0.365
1997 Hajduk PJ, Olejniczak aET, Fesik SW. One-Dimensional Relaxation- and Diffusion-Edited NMR Methods for Screening Compounds That Bind to Macromolecules Journal of the American Chemical Society. 119: 12257-12261. DOI: 10.1021/Ja9715962  0.391
1997 Sattler M, Fesik SW. Resolving Resonance Overlap in the NMR Spectra of Proteins from Differential Lanthanide-Induced Shifts Journal of the American Chemical Society. 119: 7885-7886. DOI: 10.1021/Ja971356M  0.313
1997 Olejniczak ET, Hajduk PJ, Marcotte PA, Nettesheim DG, Meadows RP, Edalji R, Holzman TF, Fesik SW. Stromelysin Inhibitors Designed from Weakly Bound Fragments: Effects of Linking and Cooperativity Journal of the American Chemical Society. 119: 5828-5832. DOI: 10.1021/Ja9702780  0.398
1996 Huang B, Eberstadt M, Olejniczak ET, Meadows RP, Fesik SW. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Nature. 384: 638-41. PMID 8967952 DOI: 10.1038/384638A0  0.354
1996 Sattler M, Fesik SW. Use of deuterium labeling in NMR: overcoming a sizeable problem. Structure (London, England : 1993). 4: 1245-9. PMID 8939758 DOI: 10.1016/S0969-2126(96)00133-5  0.396
1996 Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for proteins: SAR by NMR Science. 274: 1531-1534. PMID 8929414 DOI: 10.1126/Science.274.5292.1531  0.424
1996 Lomasney JW, Cheng HF, Wang LP, Kuan Y, Liu S, Fesik SW, King K. Phosphatidylinositol 4,5-bisphosphate binding to the pleckstrin homology domain of phospholipase C-delta1 enhances enzyme activity. The Journal of Biological Chemistry. 271: 25316-26. PMID 8810295 DOI: 10.1074/Jbc.271.41.25316  0.314
1996 Yu L, Zhu CX, Tse-Dinh YC, Fesik SW. Backbone dynamics of the C-terminal domain of Escherichia coli topoisomerase I in the absence and presence of single-stranded DNA Biochemistry. 35: 9661-9666. PMID 8703937 DOI: 10.1021/Bi960507F  0.356
1996 Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS, Nettesheim D, Chang BS, Thompson CB, Wong SL, Ng SL, Fesik SW. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature. 381: 335-41. PMID 8692274 DOI: 10.1038/381335A0  0.371
1996 Liang H, Petros AM, Meadows RP, Yoon HS, Egan DA, Walter K, Holzman TF, Robins T, Fesik SW. Solution structure of the DNA-binding domain of a human papillomavirus E2 protein: evidence for flexible DNA-binding regions. Biochemistry. 35: 2095-103. PMID 8652551 DOI: 10.1021/Bi951932W  0.381
1996 Zhou MM, Huang B, Olejniczak ET, Meadows RP, Shuker SB, Miyazaki M, Trüb T, Shoelson SE, Fesik SW. Structural basis for IL-4 receptor phosphopeptide recognition by the IRS-1 PTB domain. Nature Structural Biology. 3: 388-93. PMID 8599766 DOI: 10.1038/Nsb0496-388  0.541
1995 Zhou MM, Fesik SW. Structure and function of the phosphotyrosine binding (PTB) domain Progress in Biophysics and Molecular Biology. 64: 221-235. PMID 8987385 DOI: 10.1016/S0079-6107(96)00005-3  0.535
1995 Zhou MM, Harlan JE, Wade WS, Crosby S, Ravichandran KS, Burakoff SJ, Fesik SW. Binding affinities of tyrosine-phosphorylated peptides to the COOH-terminal SH2 and NH2-terminal phosphotyrosine binding domains of Shc Journal of Biological Chemistry. 270: 31119-31123. PMID 8537373 DOI: 10.1074/Jbc.270.52.31119  0.54
1995 Zhou MM, Ravichandran KS, Olejniczak EF, Petros AM, Meadows RP, Sattler M, Harlan JE, Wade WS, Burakoff SJ, Fesik SW. Structure and ligand recognition of the phosphotyrosine binding domain of Shc. Nature. 378: 584-92. PMID 8524391 DOI: 10.1038/378584A0  0.548
1995 Yu L, Zhu CX, Tse-Dinh YC, Fesik SW. Solution structure of the C-terminal single-stranded DNA-binding domain of Escherichia coli topoisomerase I. Biochemistry. 34: 7622-8. PMID 7779808 DOI: 10.1021/Bi00023A008  0.373
1995 Harlan JE, Yoon HS, Hajduk PJ, Fesik SW. Structural characterization of the interaction between a pleckstrin homology domain and phosphatidylinositol 4,5-bisphosphate. Biochemistry. 34: 9859-64. PMID 7632686 DOI: 10.1021/Bi00031A006  0.351
1995 Zhou MM, Meadows RP, Logan TM, Yoon HS, Wade WS, Ravichandran KS, Burakoff SJ, Fesik SW. Solution structure of the Shc SH2 domain complexed with a tyrosine-phosphorylated peptide from the T-cell receptor. Proceedings of the National Academy of Sciences of the United States of America. 92: 7784-8. PMID 7544002 DOI: 10.1073/Pnas.92.17.7784  0.53
1995 Panigot MJ, Fesik SW, Curley RW. Synthesis of [u‐13C,15N]‐cysteine hydrochloride: An important tool for heteronuclear, multi‐dimensional NMR studies of proteins Journal of Labelled Compounds and Radiopharmaceuticals. 36: 439-444. DOI: 10.1002/Jlcr.2580360506  0.36
1994 Yoon HS, Hajduk PJ, Petros AM, Olejniczak ET, Meadows RP, Fesik SW. Solution structure of a pleckstrin-homology domain. Nature. 369: 672-5. PMID 8208296 DOI: 10.1038/369672A0  0.387
1994 Zhou MM, Logan TM, Thèriault Y, Van Etten RL, Fesik SW. Backbone 1H, 13C, and 15N assignments and secondary structure of bovine low molecular weight phosphotyrosyl protein phosphatase Biochemistry. 33: 5221-5229. PMID 8172896 DOI: 10.1021/Bi00183A027  0.691
1994 Hansen AP, Petros AM, Meadows RP, Nettesheim DG, Mazar AP, Olejniczak ET, Xu RX, Pederson TM, Henkin J, Fesik SW. Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator. Biochemistry. 33: 4847-64. PMID 8161544 DOI: 10.1021/Bi00182A013  0.367
1994 Harlan JE, Hajduk PJ, Yoon HS, Fesik SW. Pleckstrin homology domains bind to phosphatidylinositol-4,5-bisphosphate. Nature. 371: 168-70. PMID 8072546 DOI: 10.1038/371168A0  0.35
1994 Liang H, Olejniczak ET, Mao X, Nettesheim DG, Yu L, Thompson CB, Fesik SW. The secondary structure of the ets domain of human Fli-1 resembles that of the helix-turn-helix DNA-binding motif of the Escherichia coli catabolite gene activator protein. Proceedings of the National Academy of Sciences of the United States of America. 91: 11655-9. PMID 7972119 DOI: 10.1073/Pnas.91.24.11655  0.381
1994 Hansen AP, Petros AM, Meadows RP, Fesik SW. Backbone dynamics of a two-domain protein: 15N relaxation studies of the amino-terminal fragment of urokinase-type plasminogen activator. Biochemistry. 33: 15418-24. PMID 7803405 DOI: 10.1021/Bi00255A023  0.318
1994 Liang H, Mao X, Olejniczak ET, Nettesheim DG, Yu L, Meadows RP, Thompson CB, Fesik SW. Solution structure of the ets domain of Fli-1 when bound to DNA. Nature Structural Biology. 1: 871-5. PMID 7773776 DOI: 10.1038/Nsb1294-871  0.362
1994 Logan TM, Zhou MM, Nettesheim DG, Meadows RP, Van Etten RL, Fesik SW. Solution structure of a low molecular weight protein tyrosine phosphatase. Biochemistry. 33: 11087-96. PMID 7727361 DOI: 10.1021/Bi00203A005  0.712
1994 Petros AM, Fesik SW. Nuclear magnetic resonance methods for studying protein-ligand complexes. Methods in Enzymology. 239: 717-739. PMID 7530321 DOI: 10.1016/S0076-6879(94)39027-4  0.327
1994 Yu L, Fesik SW. pH titration of the histidine residues of cyclophilin and FK506 binding protein in the absence and presence of immunosuppressant ligands. Biochimica Et Biophysica Acta. 1209: 24-32. PMID 7524680 DOI: 10.1016/0167-4838(94)90132-5  0.367
1994 Yu L, Meadows RP, Wagner R, Fesik SW. NMR Studies of the FK506 Binding-Protein Bound to a Spin-Labeled Ascomycin Analog Journal of Magnetic Resonance, Series B. 104: 77-80. PMID 7517786 DOI: 10.1006/Jmrb.1994.1056  0.344
1994 Curley RW, Panigot MJ, Hansen AP, Fesik SW. Stereospecific assignments of glycine in proteins by stereospecific deuteration and 15N labeling Journal of Biomolecular Nmr. 4: 335-340. PMID 7517241 DOI: 10.1007/Bf00179344  0.323
1994 Meadows RP, Olejniczak ET, Fesik SW. A computer-based protocol for semiautomated assignments and 3D structure determination of proteins. Journal of Biomolecular Nmr. 4: 79-96. PMID 7510556 DOI: 10.1007/Bf00178337  0.364
1994 Logan TM, Thériault Y, Fesik SW. Structural characterization of the FK506 binding protein unfolded in urea and guanidine hydrochloride. Journal of Molecular Biology. 236: 637-48. PMID 7508991 DOI: 10.1006/Jmbi.1994.1173  0.393
1994 Wang GT, Lane B, Fesik SW, Petros A, Luly J, Krafft GA. Synthesis and FKBP binding of small molecule mimics of the tricarbonyl region of FK506 Bioorganic and Medicinal Chemistry Letters. 4: 1161-1166. DOI: 10.1016/S0960-894X(01)80248-1  0.357
1993 Logan TM, Olejniczak ET, Xu RX, Fesik SW. A general method for assigning NMR spectra of denatured proteins using 3D HC(CO)NH-TOCSY triple resonance experiments. Journal of Biomolecular Nmr. 3: 225-31. PMID 8477187 DOI: 10.1007/Bf00178264  0.333
1993 Thériault Y, Logan TM, Meadows R, Yu L, Olejniczak ET, Holzman TF, Simmer RL, Fesik SW. Solution structure of the cyclosporin A/cyclophilin complex by NMR. Nature. 361: 88-91. PMID 8421500 DOI: 10.1038/361088A0  0.366
1993 Fesik SW. NMR structure-based drug design. Journal of Biomolecular Nmr. 3: 261-9. PMID 7689377 DOI: 10.1007/Bf00212513  0.336
1993 Xu RX, Nettesheim D, Olejniczak ET, Meadows R, Gemmecker G, Fesik SW. 1H, 13C, and 15N assignments and secondary structure of the FK506 binding protein when bound to ascomycin. Biopolymers. 33: 535-50. PMID 7682113 DOI: 10.1002/Bip.360330404  0.353
1993 Xu RX, Meadows RP, Fesik SW. Heteronuclear 3D NMR studies of water bound to an FK506 binding protein/immunosuppressant complex. Biochemistry. 32: 2473-80. PMID 7680570 DOI: 10.1021/Bi00061A004  0.322
1993 Meadows RP, Nettesheim DG, Xu RX, Olejniczak ET, Petros AM, Holzman TF, Severin J, Gubbins E, Smith H, Fesik SW. Three-dimensional structure of the FK506 binding protein/ascomycin complex in solution by heteronuclear three- and four-dimensional NMR. Biochemistry. 32: 754-65. PMID 7678499 DOI: 10.1021/Bi00054A004  0.333
1993 Petros AM, Luly JR, Liang H, Fesik SW. Conformation of an FK506 analog in aqueous solution is similar to the FKBP-bound conformation of FK506 Journal of the American Chemical Society. 115: 9920-9924. DOI: 10.1021/Ja00075A007  0.369
1992 Petros AM, Neri P, Fesik SW. Identification of solvent-exposed regions of an FK-506 analog, ascomycin, bound to FKBP using a paramagnetic probe. Journal of Biomolecular Nmr. 2: 11-8. PMID 1384850 DOI: 10.1007/Bf02192797  0.306
1992 Edalji R, Pilot-Matias TJ, Pratt SD, Egan DA, Severin JM, Gubbins EG, Petros AM, Fesik SW, Burres NS, Holzman TF. High-level expression of recombinant human FK-binding protein from a fusion precursor. Journal of Protein Chemistry. 11: 213-23. PMID 1382438 DOI: 10.1007/Bf01024859  0.394
1992 Petros AM, Kawai M, Luly JR, Fesik SW. Conformation of two non-immunosuppressive FK506 analogs when bound to FKBP by isotope-filtered NMR. Febs Letters. 308: 309-14. PMID 1380470 DOI: 10.1016/0014-5793(92)81300-B  0.345
1992 Petros AM, Gemmecker G, Neri P, Olejniczak ET, Nettesheim D, Xu RX, Gubbins EG, Smith H, Fesik SW. NMR studies of an FK-506 analog, [U-13C]ascomycin, bound to FK-506-binding protein. Journal of Medicinal Chemistry. 35: 2467-73. PMID 1377749 DOI: 10.1021/Jm00091A015  0.377
1992 Logan TM, Olejniczak ET, Xu RX, Fesik SW. Side chain and backbone assignments in isotopically labeled proteins from two heteronuclear triple resonance experiments Febs Letters. 314: 413-418. PMID 1281793 DOI: 10.1016/0014-5793(92)81517-P  0.308
1992 Kofron JL, Kuzmic P, Kishore V, Gemmecker G, Fesik SW, Rich DH. Lithium chloride perturbation of cis-trans peptide bond equilibria: Effect on conformational equilibria in cyclosporin A and on time-dependent inhibition of cyclophilin Journal of the American Chemical Society. 114: 2670-2675. DOI: 10.1021/Ja00033A047  0.352
1992 Erickson JW, Fesik SW. Chapter 29. Macromolecular X-Ray Crystallography and NMR as Tools for Structure-based Drug Design Annual Reports in Medicinal Chemistry. 27: 271-289. DOI: 10.1016/S0065-7743(08)60427-3  0.356
1991 Fesik SW, Gampe RT, Eaton HL, Gemmecker G, Olejniczak ET, Neri P, Holzman TF, Egan DA, Edalji R, Simmer R. NMR studies of [U-13C]cyclosporin A bound to cyclophilin: bound conformation and portions of cyclosporin involved in binding. Biochemistry. 30: 6574-83. PMID 2054356 DOI: 10.1021/Bi00240A030  0.416
1991 Makriyannis A, DiMeglio CM, Fesik SW. Anesthetic steroid mobility in model membrane preparations as examined by high-resolution 1H and 2H NMR spectroscopy. Journal of Medicinal Chemistry. 34: 1700-3. PMID 2033593 DOI: 10.1021/Jm00109A024  0.473
1990 Eaton HL, Austin RE, Fesik SW, Martin SF. NMR study of the possible interaction in solution of angiotensin II with a peptide encoded by angiotensin II complementary RNA. Proceedings of the National Academy of Sciences of the United States of America. 86: 9767-9. PMID 2481315 DOI: 10.1073/Pnas.86.24.9767  0.303
1990 Fesik SW, Gampe RT, Holzman TF, Egan DA, Edalji R, Luly JR, Simmer R, Helfrich R, Kishore V, Rich DH. Isotope-edited NMR of cyclosporin A bound to cyclophilin: evidence for a trans 9,10 amide bond. Science (New York, N.Y.). 250: 1406-9. PMID 2255910 DOI: 10.1126/Science.2255910  0.339
1990 Fesik SW, Zuiderweg ER. Heteronuclear three-dimensional NMR spectroscopy of isotopically labelled biological macromolecules. Quarterly Reviews of Biophysics. 23: 97-131. PMID 2188281 DOI: 10.1017/S0033583500005515  0.32
1990 Goldman RC, Fesik SW, Doran CC. Role of protonated and neutral forms of macrolides in binding to ribosomes from gram-positive and gram-negative bacteria. Antimicrobial Agents and Chemotherapy. 34: 426-431. PMID 2159256 DOI: 10.1128/Aac.34.3.426  0.319
1990 Fesik SW, Zuiderweg ER, Olejniczak ET, Gampe RT. NMR methods for determining the structures of enzyme/inhibitor complexes as an aid in drug design. Biochemical Pharmacology. 40: 161-7. PMID 2115336 DOI: 10.1016/0006-2952(90)90191-M  0.361
1990 Zuiderweg ERP, McIntosh LP, Dahlquist FW, Fesik SW. Three-dimensional 13C-resolved proton NOE spectroscopy of uniformly 13C-labeled proteins for the NMR assignment and structure determination of larger molecules Journal of Magnetic Resonance (1969). 86: 210-216. DOI: 10.1016/0022-2364(90)90228-2  0.373
1989 Zuiderweg ER, Fesik SW. Heteronuclear three-dimensional NMR spectroscopy of the inflammatory protein C5a. Biochemistry. 28: 2387-91. PMID 2730871 DOI: 10.1021/Bi00432A008  0.315
1989 Fesik SW, Gampe RT, Zuiderweg ERP. Heteronuclear three-dimensional NMR spectroscopy. Natural abundance carbon-13 chemical shift editing of 1H-1H COSY spectra Journal of the American Chemical Society. 111: 770-772. DOI: 10.1021/Ja00184A077  0.313
1988 Sham HL, Bolis G, Stein HH, Fesik SW, Marcotte PA, Plattner JJ, Rempel CA, Greer J. Renin inhibitors. Design and synthesis of a new class of conformationally restricted analogues of angiotensinogen. Journal of Medicinal Chemistry. 31: 284-95. PMID 3276890 DOI: 10.1021/Jm00397A003  0.364
1988 Fesik SW, Luly JR, Erickson JW, Abad-Zapatero C. Isotope-edited proton NMR study on the structure of a pepsin/inhibitor complex. Biochemistry. 27: 8297-8301. PMID 3149502 DOI: 10.1021/Bi00422A001  0.364
1988 Gampe RT, Connolly PJ, Rockway T, Fesik SW. Two-dimensional NMR studies of [Pro-10] atrial natriuretic factor [7-23]. Biopolymers. 27: 313-321. PMID 2965921 DOI: 10.1002/Bip.360270210  0.313
1988 Fesik SW. Isotope-edited NMR spectroscopy Nature. 332: 865-866. DOI: 10.1038/332865A0  0.314
1987 Fesik SW, Bolis G, Sham HL, Olejniczak ET. Structure refinement of a cyclic peptide from two-dimensional NMR data and molecular modeling. Biochemistry. 26: 1851-1859. PMID 3297134 DOI: 10.1021/Bi00381A010  0.317
1987 Fesik SW, Luly JR, Stein HH, BaMaung N. Amide proton exchange rates of a bound pepsin inhibitor determined by isotope-edited proton NMR experiments. Biochemical and Biophysical Research Communications. 147: 892-898. PMID 2822045 DOI: 10.1016/S0006-291X(87)80154-7  0.32
1985 Herrin TR, Thomas AM, Perun TJ, Mao JC, Fesik SW. Preparation of biologically active ristocetin derivatives: replacements of the 1'-amino group. Journal of Medicinal Chemistry. 28: 1371-1375. PMID 4032439 DOI: 10.1021/Jm00147A047  0.325
1985 Fesik SW, Holleman WH, Perun TJ. Two-dimensional 1H NMR studies of rat atrial natriuretic factor(1-23). Biochemical and Biophysical Research Communications. 131: 517-523. PMID 2932103 DOI: 10.1016/0006-291X(85)91266-5  0.311
1984 Hunt CT, Boulanger Y, Fesik SW, Armitage IM. NMR analysis of the structure and metal sequestering properties of metallothioneins. Environmental Health Perspectives. 54: 135-45. PMID 6734553 DOI: 10.1289/Ehp.8454135  0.57
1984 Fesik SW, Armitage IM, Ellestad GA, McGahren WJ. Nuclear magnetic resonance studies on the interaction of avoparcin with model receptors of bacterial cell walls. Molecular Pharmacology. 25: 281-6. PMID 6700574  0.532
1984 Fesik SW, Armitage IM, Ellestad GA, McGahren WJ. Nuclear magnetic resonance studies on the antibiotic avoparcin, Conformational properties in relation to antibacterial activity. Molecular Pharmacology. 25: 275-80. PMID 6700573  0.526
1983 Makriyannis A, Fesik S. Mechanism of steroid anesthetic action: interactions of alphaxalone and delta 16-alphaxalone with bilayer vesicles. Journal of Medicinal Chemistry. 26: 463-5. PMID 6834378 DOI: 10.1021/Jm00358A001  0.431
1983 Boulanger Y, Goodman CM, Forte CP, Fesik SW, Armitage IM. Model for mammalian metallothionein structure. Proceedings of the National Academy of Sciences of the United States of America. 80: 1501-5. PMID 6572910 DOI: 10.1073/Pnas.80.6.1501  0.58
1983 Strain SM, Fesik SW, Armitage IM. Structure and metal-binding properties of lipopolysaccharides from heptoseless mutants of Escherichia coli studied by 13C and 31P nuclear magnetic resonance. The Journal of Biological Chemistry. 258: 13466-77. PMID 6358205  0.534
1983 Strain SM, Fesik SW, Armitage IM. Characterization of lipopolysaccharide from a heptoseless mutant of Escherichia coli by carbon 13 nuclear magnetic resonance. The Journal of Biological Chemistry. 258: 2906-10. PMID 6338007  0.518
1983 MAKRIYANNIS A, FESIK S. ChemInform Abstract: MECHANISM OF STEROID ANESTHETIC ACTION: INTERACTIONS OF ALPHAXALONE AND Δ16-ALPHAXALONE WITH BILAYER VESICLES Chemischer Informationsdienst. 14. DOI: 10.1002/chin.198334355  0.352
1983 DE JONG AP, FESIK SW, MAKRIYANNIS A. ChemInform Abstract: CONFORMATIONAL REQUIREMENTS FOR NOREPINEPHRINE UPTAKE INHIBITION BY PHENETHYLAMINES IN BRAIN SYNAPTOSOMES. EFFECTS OF α-ALKYL SUBSTITUTION Chemischer Informationsdienst. 14. DOI: 10.1002/chin.198322358  0.359
1982 de Jong AP, Fesik SW, Makriyannis A. Conformational requirements for norepinephrine uptake inhibition by phenethylamines in brain synaptosomes. Effects of alpha-alkyl substitution. Journal of Medicinal Chemistry. 25: 1438-41. PMID 7154004 DOI: 10.1002/Chin.198322358  0.461
1982 Makriyannis A, Fesik S. Methoxy group conformations of phenyl methyl ethers in solution Journal of the American Chemical Society. 104: 6462-6463. DOI: 10.1021/Ja00387A058  0.422
1980 Makriyannis A, Fesik SW. Effects of anesthetics on sulfate transport in the red cell. Journal of Neuroscience Research. 5: 25-33. PMID 7381978 DOI: 10.1002/Jnr.490050105  0.431
1980 Weintraub HJ, Nichols DE, Makriyannis A, Fesik SW. Conformational energy differences between side chain alkylated analogues of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane. Journal of Medicinal Chemistry. 23: 339-41. PMID 7365752 DOI: 10.1002/Chin.198034159  0.468
1980 Makriyannis A, Fesik S. Specific perturbations in erythrocyte membranes and lipid bilayers by anesthetic steroids Drug and Alcohol Dependence. 6: 77. DOI: 10.1016/0376-8716(80)90406-8  0.4
1980 WEINTRAUB HJR, NICHOLS DE, MAKRIYANNIS A, FESIK SW. ChemInform Abstract: CONFORMATIONAL ENERGY DIFFERENCES BETWEEN SIDE CHAIN ALKYLATED ANALOGS OF THE HALLUCINOGEN 1-(2,5-DIMETHOXY-4-METHYLPHENYL)-2-AMINOPROPANE Chemischer Informationsdienst. 11. DOI: 10.1002/chin.198034159  0.351
Show low-probability matches.